Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06417190 | RECRUITING | Muscle-Invasive Bladder Carcinoma

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Sponsor:

Leslie Ballas

Information provided by (Responsible Party):

Leslie Ballas

Brief Summary:

This is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or without immunotherapy (IO) followed by trimodal therapy (TMT). Enrolled patients will undergo at least 3 cycles of NAC +/- IO (oncologist's choice) followed by a four- or six-week course of concurrent standard of care chemotherapy and radiation therapy. These patients will be compared with historical controls of patients with a diagnosis of pure urothelial carcinoma who have undergone TMT. This study has been designed to test the hypothesis that variant histology TMT can be delivered within 45 days of NAC +/- IO and is therefore a viable option in patients who are risk of systemic disease spread.

Condition or disease

Muscle-Invasive Bladder Carcinoma

Tumor

Intervention/treatment

Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)

Phase

PHASE2

Detailed Description:

Trimodal therapy (TMT) is accepted as an NCCN category 1 alternative to radical cystectomy (with neoadjuvant chemotherapy) in patients with cT2N0M0 muscle-invasive urothelial cell bladder cancer (MIBC). Not all patients with MIBC have pure urothelial cell carcinoma; urothelial carcinoma with variant histology (VH) described any morphologic variant of conventional urothelial carcinoma that is believed to be derived from urothelial carcinoma and is typically admixed with conventional urothelial carcinoma in the same tumor. Variant histologies described include squamous differentiation, glandular differentiation, micropapillary, sarcomatoid, small cell/neuroendocrine, plasmacytoid and nested variant. This is a rare tumor type and understudied. For patients with variant histologies there is limited data on the use of trimodal therapy. There are a couple single institution retrospective studies and data from the NCDB, but no prospective data.

Study Type : INTERVENTIONAL
Estimated Enrollment : 20 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : IIT2023-13-BALLAS-VHTMT: Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Actual Study Start Date : 2025-12-01
Estimated Primary Completion Date : 2030-12
Estimated Study Completion Date : 2030-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Documented diagnosis of MIBC with variant histology, cT2-T4N0M0, confirmed by TURBT and CT C/A/P and/or PET.
  • * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion Criteria
  • * Evidence of diffuse cis on pathology
  • * Presence of bilateral hydronephrosis (if hydronephrosis is present, can only be unilateral)
  • * Prior radiotherapy to the pelvis
  • * History of systemic therapy for MIBS
  • * Presence of concurrent cancer (remote history of cancer (\>5 years) allowed if the patient is without evidence of disease)
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Location Details

NCT06417190

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Cedars Sinai Medical Center

Los Angeles, California, United States, 90048